Illumina, Inc. vs Spotify Technology — how do they compare? Illumina, Inc. trades at $264.24 (market cap $40.43B), while Spotify Technology trades at $526.7 (market cap $105.45B). The key difference: Spotify Technology is far larger — about 2.6× Illumina, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Spotify Technology for 111 Days on average.
| ILMN | SPOT | |
|---|---|---|
Market Cap | $40.43B | $105.45B |
Volume | 2,948,626 | 2,000,851 |
Sector | Health | Media |
52-Week High | $293.69 | $692.04 |
52-Week Low | $91.00 | $412.75 |
Typical Hold Time | 83 Days | 111 Days |
Enterprise Value | $41.79B | $95.41B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Spotify (SPOT) trades at $512.92, up 5.08% with strong bullish momentum. The stock shows robust fundamentals with revenue growth from $17.19B in 2025 to projected $18.1B in 2026, while net income margin expanded to 18.43%. Technical indicators signal bullish sentiment with price above key support at $497. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending.
Outlook remains positive with analyst consensus target of $608.18 representing 18.6% upside. Key opportunities include gross margin expansion and new monetization tools, while risks involve competitive pressures and market volatility. Wall Street maintains strong buy sentiment with 62% of analysts recommending purchase.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →